

Index

- ABD. *See* actin binding domain
- actin(s)
- collapsing, in lamellipodia, 189
 - lamellipodia and, 190
 - myosin proteins and, 190
- actin binding domain (ABD), 310
- actin filaments, 28
- in microtubular mechanotransduction, 241
- α -actinin, 121, 310, 312, 315
- ABD and, 310
 - conformational states of, 123f
 - modular structure/binding sites of, 311f
 - SMD for, 312–13
 - spectrin repeats in, 310, 315
- β -actinin, 121
- conformational states of, 123f
 - RGD peptides and, 122
- adenomatous polyposis coli (APC), 239
- adhering cells, 225
- in ECs, 228
- adhesion-complex proteins, 127, 280
- affixin, 189
- agonist-independent constitutive activity, 102
- amino acids, 274
- anchorage-dependent cells, 212
- angiotensins, 104–5
- vasoactive peptides, 104
- anisotropic cell spreading, 182
- ankyrin(s), 171
- ankyrin proteins, 315–16
- ankyrin repeats, 291–92
- antibodies
- ligand density and, 135
 - nonperturbing, ligand density and, 137
- aortic valve leaflets, 50
- APC. *See* adenomatous polyposis coli
- aPKC. *See* atypical protein kinase C
- apoptotic blebbing, 187
- arterial walls, thickness of, 1
- arthritis, 2
- associated cytoskeleton (CSK), 90
- cell membranes and, 90
- atherogenesis, 22
- development of, 254–55
 - glycocalyx and, 35
- atherogenic phenotypes, in ECs, 62
- atheroprotective phenotypes, in endothelium
- mechanotransduction, 47
- atherosclerosis, 22, 35–36, 269
- calcific aortic valve sclerosis, 48–51
 - G-proteins and, 89
 - risk factors for, 89
- atomic force microscopy (AFM), 286
- for ECs, 63
 - for endothelial mechanotransduction, 26
 - for focal adhesion complexes, 254
 - mechanical forces with, 380–82, 381f
 - protein conformational change with, 323–25
 - in vitro* tests with, 5
- atypical protein kinase C (aPKC), 239
- autocrine signaling, 339–57
- bridge modeling for, 353–56
 - in bronchial epithelium, 340–41
 - cell culture setup for, 341f
 - cellular/extracellular geometry changes, 341, 344

- autocrine signaling (*cont.*)
 - cellular viscoelasticity and, 356
 - constrained, 11–12
 - in EGFR system, 344–5
 - FE method for, 349
 - fluid drag and, 356
 - governing parameters for, 349–51
 - hypothesis testing for, 346–8
 - implications of, 356–57
 - interstitial geometry and, 339
 - ligand concentrations and, 344, 346f, 347–9
 - LIS and, 341, 344, 346
 - local loops, 344–45, 345f
 - in lungs, 340f, 341
 - through MAPK, 341
 - MD for, 347
 - rate sensitivity of, 351–52
 - two-photon microscopy and, 343f, 353
- B₂. *See* bradykinin
- BAECs. *See* bovine aortic endothelial cells
- basal cells, 161
- basal membrane, 61
- BDM. *See* butadiene monoxime; 2,3-butanedione monoxime; 2,3-butanedione monoxime (BDM)
- bead forcing, *in vitro* tests with, 5
- benzyl alcohol, 93
- blebbing motility, 187–88
 - apoptotic, 187
 - cell spreading and, 187
 - mitosis and, 187
 - MRLC phosphorylation and, 187
 - myosin proteins and, 187
 - PLC and, 188
 - tumor cell migration and, 187
- blebbistatin, 139, 144
- BMP4. *See* bone morphogenic protein 4
- bone cells, 269
 - endochondrial ossification in, 405
 - osteoblasts, 405
 - osteoclasts, 405
 - remodeling, 404–5
- bone morphogenic protein 4 (BMP4), 51
- bone remodeling, 404–5
- bovine aortic endothelial cells (BAECs), 69, 70f
 - in Cl[−] ion channels, 164, 166
 - in flow-sensitive ion channels, 163, 174
 - G-proteins and, 89
 - shear stress and, 89
- bradykinin (B₂), 104–5
- bronchial epithelium, autocrine signaling in, 340–42
 - MAP and, 342
- butadiene monoxime (BDM), 133
- calcific aortic valve sclerosis, 48–51
 - BMP4 and, 51
 - causes of, 49
 - features of, 48–50, 49f
 - leaflets in, 50
- calcium, 126
 - in intracellular oscillations, 162
- calmodulin, 294–95
- cancers, 15
- carotid bifurcation model, 364f
- cartilage, tensegrity in, 209
- cause-and-effect hypothesis, for endothelial mechanotransduction, 48
- caveolae
 - cholesterol in, 101
 - coat proteins in, 42, 101
 - in ECs, 68
 - sphingolipids in, 101
- cell(s)
 - adhering, 225
 - anchorage-dependent, 212
 - bone, 269
 - compression struts in, 207
 - cytoplasmic region of, 223–24, 230
 - eukaryotic, 169, 236
 - force levels in, 12–15, 13t
 - gated ion channels in, 234–35
 - gene transcription in, 212
 - GFP-LamA in, 224f
 - localized distortion in, 212
 - mechanical force and, molecular function, 286–89
 - mechanical forces on, 269–70, 407
 - mechanical forces on, responses by, 379
 - mechanosensing in, 181–91, 442
 - as mechanotransducer, 212–13
 - metabolism of, 197
 - muscle, 209, 269
 - nucleated, 203f
 - nuclei measurements for, 222

- organelles in, 230
- permeabilized, 204
- properties of, 184–91
- signal transduction in, 212
- stem, 143, 269
- stiffness in, 204
- as tensegrity structures, 202–6
- towed growth in, 234
- cell–cell junctional proteins, 63
- CellMAP program, 187–88
- cell membrane fluctuations (CMF), 99–100
 - free volume theory and, 100
 - in red blood cells, 100
 - Saffman hydrodynamic theory and, 100
- cell membranes,
 - altered gene expression in, 64
 - in animals, 65
 - basal, 61
 - bilayer modulation in, 64–65
 - CMF and, 99–100
 - CSK and, 90
 - diffusive dynamics of, 100
 - flow-sensitive ion channels and, 171–72
 - fluidity of, 65–67, 172
 - ion channels and, 161, 166
 - lipid molecules in, 65
 - as mechanosensor, 64–75
 - phospholipids in, 65
 - pressure profiles in, 91, 91f
 - structure of, 65
- cell metabolism, tensegrity and, 194
- cell migration, 135, 138
 - body translocation in, 138
 - computational modeling for, 135
 - debris after, 138
 - lamellipodium protrusion in, 138
 - limited neural crest, 135
 - regulation of, 136
 - substratum adhesions in, 138
 - three-dimensionality of ECM, 146, 149f
 - trailing edge retraction in, 138
- cell signaling, endothelial,
 - mechanotransduction in, 21
- cell spreading, 182
 - anisotropic, 182
 - blebbing motility and, 187
 - isotropic, 182
- cell surface integrins, 161
- cell-to-cell forces, in ECM, 129
- cellular cytoskeletal network, 161
- cellular mechanotransduction. *See*
 - mechanotransduction, cellular
- cholera-toxin-B (CT-B), 69
- cholesterol, in ECs, 66
 - in caveolae, 101
 - integrin-mediated mechanotransduction and, 72–73
 - in lipid bilayers, 93
 - in lipid domains, 69
- chromatins, in nuclear mechanics, 226
- chromosomes, nuclear mechanics and, 227
- ciliary vibrations, 289
- circumferential stress (CS), 360–74
 - carotid bifurcation model for, 364f
 - in ECs, 359, 365–72
 - influencing factors for, 362–63, 364
 - intercellular junctions and, 373
 - physiological background of, 360–65
 - SED and, 373
 - simultaneous stretch/shear methods in, 365–66
 - SPA and, 361–74
 - stretch/shear mechanism for, 372–73
 - tension and, 373
- CLA. *See* conjugated linoleic acid
- cLAD. *See* left descending anterior coronary artery
- Cl[−] ion channels, 164–66
 - BAECs in, 164, 166
 - desensitization in, 165
 - ECs in, 165
 - fluid flow in, 165
 - in HAECs, 166
 - VRAC in, 166
- CMF. *See* cell membrane fluctuations
- coat proteins, 42, 101
- collagen, 140
 - in microtubular mechanotransduction, 234
- complex modulus, 29–30
- compression strain, on stem cells, 408–10, 412–13
 - devices for, 409f
- compression struts, 207
- conjugated linoleic acid (CLA), 372
- constitutive models, of proteins, 276–77

- continuous protrusion, in cell
 - mechanosensing, 188–89
 - affixin and, 189
 - WAVE1 and, 189
- contractile forces, 129
- contractile waves, 189
- control feedback system, NPCs as, 425f, 434
- CPC. *See* phospholipase C
- CREEP program, 187
- CS. *See* circumferential stress
- CSK. *See* associated cytoskeleton
- CT-B. *See* cholera-toxin-B
- cysteines, 289
 - disulfide bonds and, 295–96
- cytoplasm
 - nuclear mechanics in, 223–24, 230
 - organelles in, 230
- cytoskeletal proteins
 - cellular network of, 161
 - ECM v., 120–21
 - integrins and, 319f
 - mechanical signals in, 182
 - mechanosensing for, 181–83
 - prestresses in, 205f, 206
 - substrate priming of, 182
 - tensegrity and, 197, 209–10
 - traction forces in, 129, 130–31
- cytoskeletal transduction, 10
 - in endothelium, 10–11, 36–40
 - mechanosensors in, 10
- DCSA network. *See* distributed cytoplasmic structural actin network
- diabetes mellitus, 89
- Dictyostelium chemotaxis, 140
- Dictyostelium discoideum*, 138
- direct activation, of ion channels, 169–71, 170f
- diseases
 - arthritis, 2
 - atherosclerosis, 22, 35–6, 269
 - cancer, 15
 - diabetes mellitus, 89
 - disturbed flow in mechanotransduction and, 2
 - Emery-Dreifuss muscular dystrophy, 227
 - focal adhesion complexes and, 250
 - Hutchinson-Gifford progeria syndrome, 227
 - hyperlipidemia, 89
 - hypertension, 89
 - KLF2, 269
 - malaria, 15
 - monocytes in, 2
 - nuclear mechanics and, 227–28
 - PKD, 2
 - pulmonary, 2
 - thrombosis, 269
- distributed cytoplasmic structural actin (DCSA) network, 31
- disulfide bonds, 295–97
 - cysteine bonds and, 295–96
 - ligand binding in, 296–97
 - Mel-Cam and, 296
 - VCAM-1 and, 295, 297f
- domain deformation, 271–72
- domain motion, 271
 - elongation in, 272
 - hinge, 271–72, 277–78
 - sliding, 272
- domain unfolding, 271
- double-membrane envelope, 223
- durotaxis theory, 140, 141
 - haptotaxis and, 141
- dynamic instability, of microtubules, 238–40
 - deformation effects on, 242
 - epithelial cells and, 238
 - fibroblast cells and, 238
 - kinetochores and, 238
 - signaling and, 238–40
 - stochastic switching and, 238
- ECM. *See* extracellular matrix
- ECs. *See* endothelial cells
- EECP. *See* enhanced external counter-pulsation (EECP)
- EGF receptor (EGFR), in ECM, 150
 - ligand density in, 353f
- EGFR system. *See* epidermal growth factors receptor system
- elastic modulus, 29
- elastic substrata, 389–92
 - TFM for, 389
- ELCs. *See* essential light-chains
- electron microscopy, 121
- Emery-Dreifuss muscular dystrophy, 227
- endochondrial ossification, 405

- endothelial cells (ECs)
 - adhering cells in, 228
 - AFM for, 63
 - arterial expansion in, 361
 - atherogenic phenotypes in, 62
 - ATP release in, 169
 - BAECs in, 69, 70f
 - biological responses of, 365–72
 - biomechanics of, 28–33
 - blood flow in, 63f
 - caveoli in, 68
 - cholesterol content in, 66
 - in Cl^- ion channels, 165
 - conformation in, 162
 - CS/WSS in, 361f
 - dysfunction in, 62
 - ECM and, 121
 - EPCs, 403
 - fatty acid chain saturation in, 66
 - FCS for, 76–78, 80f
 - finite element analysis for, 73–74
 - fluid shear stress on, 3f
 - glycocalyx in, 62, 70, 171
 - hereditary integral for, 28
 - heterogeneity in, 51–52
 - homeoviscous adaptation for, 67
 - HUVECs, 94, 95f, 269
 - hydrophobic mismatch in, 67–68
 - ion channels in, 161, 164, 172–74
 - K^+ ion channels, 164
 - linear viscoelastic models for, 28, 29t
 - lipid diffusion within, 74–75
 - lipid-mediated models for, 79, 80f, 81
 - mechanosensitive functions for, 72–73
 - membrane fluidity in, 65–67
 - membrane tension effects on, 74–75
 - micrograph of, 229f
 - in microtubular mechanotransduction, 234
 - molecular organization of, 64f
 - nuclear mechanics and, 220
 - phospholipids in, 65
 - in plasma membrane
 - mechanotransduction, 61
 - protein conformational change and, 269
 - protein content in, 66
 - SMCs and, 171
 - steady flow mediation of, 167–68
 - stress–strain tissue relationships in, 28
 - traction force generation by, 133
 - vascular flow in, 221f
 - wound closure under, 72
- endothelial nitric oxide synthase (eNOS), 90
 - SPA with, 369
- endothelial progenitor stem cells (EPCs), 403
- endothelium
 - atherogenesis and, 22
 - as blood “gatekeeper,” 22
 - cardiovascular development and, 22
 - eNOS in, 90
 - functions of, 22
 - mechanosensing in, 161
 - NO productivity in, 90
 - shear stress on, 105
 - vascular permeability in, 22
- endothelium, mechanotransduction in, 20–52, 62–63
 - actin deformation in, 27
 - AFM for, 26
 - aging and, 32
 - arterial hemodynamics in, 46f
 - arterial heterogeneity in, 47–48
 - atheroprotective phenotypes in, 47
 - calcific aortic valve sclerosis and, 48–51
 - cause-and-effect hypothesis for, 48
 - cell signaling in, 21
 - complex modulus for, 29–30
 - through cytoskeleton, 36–40, 39f
 - DCSA network in, 31
 - as decentralized mechanism, 23–26, 25f
 - deformation in, 22
 - descriptors for, 22–23
 - disturbed flow for, 47
 - downstream/immediate signaling
 - responses, 27
 - elastic modulus for, 29
 - filament bundling in, 31
 - filament displacement in, 27
 - as flow-mediated mechanism, 20
 - fluid shear stress in, 39–40
 - focal adhesion in, 72
 - FRET in, 37
 - gene expression in, 47
 - GFPs in, 38
 - glycocalyx in, 26, 34–36
 - G-protein activation in, 21, 33, 34
 - hemodynamics and, 21, 51–52
 - heterogeneity in, 51–52

Cambridge University Press

978-0-521-89523-1 - Cellular Mechanotransduction: Diverse Perspectives from Molecules to Tissues

Edited by Mohammad R. K. Mofrad and Roger D. Kamm

Index

[More information](#)

450

Index

endothelium, mechanotransduction in
(*cont.*)

immunocytochemistry in, 45

integrin-mediated, 40–44, 72

intracellular prestress in, 38

ion channel activation in, 21, 33

KLF-2 in, 48

in lamellipodia, 37–38

magnetic bead twisting cytometry, 32

mechanical force conversion in, 27

mechanosensors in, 25

mechanotransducers in, 21

mechanotransmission in, 23, 26–27

membrane fluidity in, 21

microdomains in, 68

microtubule networks in, 27, 30

NO in, 35

PAK in, 44–45

PECAM-1 in, 24, 44

physical deformation in, 26

PKC in, 47–48

plasma transport characteristics in, 23

primary cilium in, 22, 26, 36

scale for, 51–52

shear stress on, 21f, 33–6, 44–45

at single cell level, 51

sinusoidal input functions, 29

soft glassy material models in, 32

spatial gradients in, 62

spatiotemporal flow responses in, 26–27

strained focusing for, 38–39

substratum adhesion sites in, 24

TCSPC microscopy for, 75

temporal gradients in, 62

tension field theory for, 33

viscoelastic models for, 30, 31t, 32

viscous modulus for, 30

in vitro phenotypes in, 45–47*in vivo* phenotypes in, 45–47

VRAC in, 33

enhanced external counterpulsation
(EECP), 373eNOS. *See* endothelial nitric oxide synthaseEPCs. *See* endothelial progenitor stem cellsepidermal growth factors receptor (EGFR)
system, 344–45

hypothesis testing for, 346–48

epithelial cells

bronchial, autocrine signaling in, 340–41

dynamic instability and, 238

ECM and, 121

tensegrity in, 209

ERK. *See* extracellular-signal-regulated
kinase

essential light-chains (ELCs), 130

MLCK, 130

eukaryotic cells

ion channels in, 171

microtubular mechanotransduction in, 236

as multimodular, 289

protein unfolding in, 289

Euler-Bernoulli beam theory, 392

Euler Bucking model, 237

extracellular matrix (ECM), 41f, 120–51

calcium in, 126

cell homeostasis by, 120

cell-to-cell forces in, 129

collagen and, 140

computational methods for, 440

contractile forces in, 129

cytoskeletal proteins v., 120–21

Dictyostelium chemotaxis and, 141

durotaxis theory and, 140–41

ECs and, 121

EGFR in, 150

elasticity of, 133

epithelial cells and, 121

FAK in, 143

fibrinogen and, 134, 137

fibroblasts in, 134, 138

fibronectins in, 120, 124, 134, 150

focal adhesion complexes in, 251

force-bearing protein networks and, 287

gels in, 207

Hooke's Law and, 140

hydrogels in, 140

integrin-mediated mechanotransduction

and, 43, 253–54

integrins in, 120–1

lamellar ruffling in, 140

laminin and, 121

ligand density and, 133–44

magnesium in, 126

manganese in, 126–27

mechanical forces on, 270, 377

mechanical strain on, 408

mechanosensing compliance and, 139–41,
143–44

- melanoma cells in, 127
- microfibrillar network in, 130
- MMPs and, 150
- myosin proteins in, 143, 251
- Poisson's ratio and, 140
- protein conformational change and, 269
- protrusive forces in, 129
- RGD peptides in, 440
- rheological properties of, 120, 139
- rigidity of, 133–34
- sensing in, 120
- shear modulus in, 140
- spring models for, 141, 143
- stem cells in, 143
- stiffness in, 141
- tensegrity and, 197, 203, 208–9
- three-dimensionality of, 144–51
- traction forces in, 129–33, 139
- vitronectin and, 134
- wound healing and, 134
- extracellular-signal-regulated kinase (ERK), 72
- integrins and, 127
- FAK. *See* focal adhesion kinase
- fatty acid chains, in ECs, 66
- FCS. *See* fluorescence correlation spectroscopy
- FCs. *See* focal complexes
- FE method. *See* finite element method
- FERM domains, 126
 - in multimodular proteins, 318
 - PTB domains and, 126
- FG repeats. *See* phenylalanine-glycine repeats
- fibrillar adhesions (FX), 129
- fibrillogenesis, 302
- fibrinogen, 134, 137
- fibroblasts
 - dynamic instability and, 238
 - ECM and, 134, 138
 - in focal adhesion complexes, in cellular mechanotransduction, 253
 - three-dimensionality of ECM and, 146
- fibronectins, 297–300, 302–3
 - cell recognition sites on, 300
 - in ECM, 120, 124, 134, 150
 - fibrillogenesis and, 302
 - in focal adhesion complexes, 252
 - FRET for, 302
 - GFP and, 302
 - lamellipodia and, 189
 - in multimodular proteins, 291f, 299
 - PDMs and, 302
 - as proteins, 280
 - quaternary structural model for, 302, 303
 - structure of, 301f
 - unfolding of, 300, 302
- filaments
 - actin deformation of, 27
 - bundling of, 31
 - in endothelial mechanotransduction, 27
- filamin, 316
 - cytoskeleton/integrin contact in, 319f
 - modular structure/binding sites of, 317f
- filopodia, 186
- filopodial motility, 186–87
 - capping proteins and, 186
 - CellMAP program for, 186–87
 - CREEP program for, 187
 - lamellar protrusion during, 187
 - paxillin molecules and, 186
 - protein families and, 186
- finite element analysis, for stress, in ECs, 73–74
- finite element (FE) method,
 - for autocrine signaling, 349
 - for ligand density, 349
- FLIM. *See* fluorescence lifetime imaging microscopy
- flow-sensitive ion channels, 161, 163–64
 - BAECs in, 163, 174
 - cell membranes and, 171–72
 - HAECs in, 163
 - HUVECs in, 163
 - MscL, 171
 - TRP in, 163
- fluid drag, 356
- fluid shear stress
 - on EC, 3f
 - in endothelial mechanotransduction, 39–40
- fluorescence correlation spectroscopy (FCS), 75–76
 - confocal volume for, 76
 - for ECs, 76–78, 80f
 - fluorescence lifetime in, 78–79
 - for lipid bilayers, 94, 95f, 96
 - for unilamellar vesicles, 76–78

- fluorescence lifetime, 78–79
 - IRF and, 78
- fluorescence lifetime imaging microscopy (FLIM), 79, 80f
- fluorescence recovery after photobleaching (FRAP), 71
 - lipid bilayers and, 94, 96
 - tensegrity and, 207
- fluorescence resonance energy transfer (FRET), 81
 - for fibronectins, 302
 - for multimodular proteins, 291f, 326, 328
 - for protein conformational change, 282, 323
- focal adhesion complexes,
 - cellular mechanotransduction in, 7f, 9–10, 250–64, 378
 - in endothelium, mechanotransduction in, 72
 - FAK, 40
 - FC in, 128
 - IAEDANS in, 10
 - in integrins, 128f
 - maturation of, 127–28
 - mechanical forces and, 287
 - mechanotransduction in, 7f, 9–10
 - shear stress and, 74f
 - tensegrity and, 203
 - Triton X and, 9
- focal adhesion complexes,
 - mechanotransduction in
 - AFM for, 254
 - BDM in, 252–53
 - biochemical signaling pathways in, 250
 - diseases and, 250
 - in ECM, 251
 - experimental studies on, 252–54
 - FAK in, 251
 - fibroblasts in, 253
 - fibronectin microbeads in, 252
 - forced-induced assembly of, 252–54
 - force regulation of, 261–62
 - force sensing proteins in, 254–59, 261
 - forces exerted by, 253–54
 - initial, 251
 - integrin-mediated ECM in, 253–54
 - maturation stages of, 251–52
 - MD for, 254
 - numerical studies on, 254–59, 261
 - Rho proteins in, 251–52
 - role of, 251
 - sustained force in, 251
 - talin in, 254–59, 255f
 - vinculin in, 254–55
- focal adhesion kinase (FAK), 40
 - in cellular mechanotransduction, 251
 - in ECM, 143
 - integrins and, 121
 - three-dimensionality of ECM, 146–47
 - traction forces and, 392
- focal complexes (FCs), 128
 - FA conversions to, 128
 - paxillin molecules in, 128
- force-bearing protein networks, 287
 - ECM and, 287
 - significance of, 287–89
- force levels, in cells, 12–15, 13t
- force sensing proteins, 254–59, 261
- formyl peptide receptors (FPRs), 104–5
- Förster resonance energy transfer (FRET), 37
- FPRs. *See* formyl peptide receptors
- FRAP. *See* fluorescence recovery after photobleaching
- free volume, 97–98
- free volume theory, 100
- FX. *See* fibrillar adhesions
- GAG polymer. *See* glycosaminoglycan polymer
- gated ion channels, 234–35
- GDP release, 107
- GEF. *See* guanine exchange factor
- gene expression, in cellular
 - mechanotransduction, 10–11
 - in cell membranes, 64
 - in endothelium, 47
 - in proteins, 270
- generalized fluorescence polarization (GP), 99
- gene transcription, 212
- GFP. *See* green fluorescent protein
- GFP-LamA, 224f
- giant unilamellar vesicles (GUVs), 97, 98f
- glycocalyx
 - arterial role of, 35
 - atherogenesis and, 35

- atherosclerosis and, 35–36
- in cellular mechanotransduction, 10
- in ECs, 62, 70, 171
- in endothelial mechanotransduction, 26, 34–36, 70
- endothelial mechanotransduction and, 26
- GAG polymer in, 34
- GPI-anchored proteins in, 34
- in ion channels, 171
- in shear stress, 5
- structure of, 34–35
- in vascular physiology, 69–70
- glycosaminoglycan (GAG) polymer, 34
- glycosylphosphatidylinositol (GPI)-anchored proteins, 34
- GP. *See* generalized fluorescence polarization
- GPCR. *See* G-protein-coupled receptors
- GPI proteins. *See* glycosylphosphatidylinositol-anchored proteins
- G-protein-coupled receptors (GPCR), 101–5
 - activation of, 103
 - agonist-independent constitutive activity, 102
 - angiotensins and, 104–5
 - bradykinin and, 104–5
 - conformational changes in, 102
 - direct stretching in, 102
 - dynamics and structure of, 101–3
 - FPRs and, 104–5
 - GDP release from, 107
 - GEF activity in, 105
 - in ion channels, 161
 - membrane protein activation in, 107
 - as “plastic,” 102
 - rhodopsin in, 101
 - shear stress in, 102
 - signal amplification cascades in, 102
 - transduction pathways and, 105–6
- G-proteins, in cellular mechanotransduction, 8–9, 33–34, 89–109
 - activation of, 21
 - activation pathways, 105–8
 - atherosclerosis and, 89
 - in BAECs, 89
 - CMF in, 99–100
 - CSK and, 90
 - GPCR, 101–5
 - heterotrimeric, 90–1
 - hydrolysis of, 67–68
 - ion channels and, 161
 - lipid bilayers and, 91–101
 - NO production in, 107–8
 - green fluorescent protein (GFP), 38, 294
 - conformational change for, 326–27, 328
 - fibronectins and, 302
 - tensegrity in, 207
 - for traction forces, 391
 - guanine exchange factor (GEF), 42
 - in GPCR, 105
 - microtubular mechanotransduction and, 244
- GUVs. *See* giant unilamellar vesicles
- HAECs. *See* human aortic endothelial cells
- haloalkane, 68
- haptotaxis, 134f
 - durotaxis theory and, 141
- hearing, cellular mechanotransduction in, 2
- heart valve tissue, calcification of, 1
- hematopoietic stem cells (HSCs), 403
- hemodynamic shear stress, 1
 - in endothelial mechanotransduction, 21
- Hooke’s Law, 28–29
 - ECM and, 140
- HSCs. *See* hematopoietic stem cells
- human aortic endothelial cells (HAECs), 163
 - Cl[−] ion channels in, 166
- human umbilical endothelial cells (HUVECs), 94, 95f, 269
 - in flow-sensitive ion channels, 163
- Hutchinson-Gifford progeria syndrome, 227
- HUVECs. *See* human umbilical endothelial cells
- hydrophobic matching, in lipid bilayers, 92
- hydrophobic mismatch, 67–68
- hydrostatic pressure, 6
- hypercholesterolemia, 51
- hyperlipidemia, 89
- hypertension, 89
- IAEDANS (fluorescent dye), 10
- ICAM-1. *See* intracellular adhesion molecule-1
- Ig-like domains, 291
 - in VCAM-1 proteins, 293

- immunocytochemistry, 45
- Importin- α , 418, 423, 425f, 426
- Importin- β , 418, 423, 425f, 426
- importins, in nucleocytoplasmic transport, 423, 425–26
- indirect activation, of ion channels, 169, 170f
- “inside-out signaling,” 126
- instrument response function (IRF), 78
- integrin(s), 120–21
 - β -actinin, 121
 - activation of, 124–27
 - adhesion-complex proteins in, 127
 - adhesion receptors in, 121
 - antibodies for, 124
 - cell surface, in ion channels, 161
 - in ECM, 120–21
 - electron microscopy for, 121
 - ERK and, 127
 - FAK and, 121, 127
 - FERM domains and, 126
 - filamin and, 319f
 - focal adhesion complexes in, 128f
 - FX in, 129
 - “inside-out signaling” for, 126
 - interference reflection microscopy for, 121
 - interleukin-2 receptors and, 124
 - lateral diffusion coefficient of, 136
 - ligand binding to, 122, 136
 - molecular structural basis for, 124
 - “outside-in signaling” for, 126–27, 139
 - as proteins, 280
 - PTB domains for, 126
 - RGD peptides and, 122
 - tensegrity and, 203
 - three-D adhesions in, 129
- integrin-mediated cell adhesions, 318
- integrin-mediated mechanotransduction, 40–4, 41f, 72
 - α -actinin, 121
 - ECM composition, 43
 - FAK in, 40
 - flow conditioning for, 42, 43–44
 - in focal adhesion complexes, 253–54
 - GEF in, 42
 - ligands and, 122f
 - MAPK in, 42
 - MCL in, 42
 - PAK activation in, 44–45
 - reduced adhesion sites in, 40
 - RGD peptides and, 122
 - spatiotemporal displacement patterns in, 40
- interference reflection microscopy, 121
- interfragmentary strain theory, 406–7
- interleukin-2 receptors, 124
- intracellular adhesion molecule-1 (ICAM-1), 307
- intracellular contraction, 12
- intracellular loading, 230
- intracellular traction, 288
- in vitro* tests, of mechanotransduction
 - with AFM, 5
 - arterial hemodynamics in, 46f
 - with bead forcing, 5
 - in endothelium, 45–47
 - hydrostatic pressure in, 6
 - of mechanosensation, 3–6, 4f
 - with shear stress, 3–5
 - with substrate stretch, 5–6
- in vivo* phenotypes, of mechanotransduction,
 - arterial hemodynamics in, 46f
 - in endothelium, 45–47
 - immunocytochemistry and, 45
- ion channels, 161–74
 - activation of, 21, 33, 166–68
 - ankyrin in, 171
 - ATP release in, 169
 - basal cell surfaces in, 161
 - cell membranes and, 161, 166
 - cell surface integrins in, 161
 - cellular cytoskeletal network in, 161
 - Cl[−], 164–66
 - direct activation of, 169–71, 170f
 - in ECs, 161, 164, 172–74
 - in eukaryotic cells, 171
 - flow mechanisms of, 168–74, 170f
 - flow-mediated vasoregulation of, 161
 - flow-sensitive, 161, 163–64
 - gated, 234–35
 - glycocalyx in, 171
 - GPCR in, 161
 - G-proteins and, 161
 - indirect activation of, 169, 170f
 - inhibition data for, 166–67
 - intracellular calcium oscillations in, 162
 - intracellular space and, 162
 - K⁺, 164
 - MAPK induction in, 162

- mechanosensitive, 162–66
- MscL, 171
- oscillatory flow in, 168, 172–74
- PECAM-1 and, 161
- SA, 198
- in SMCs, 174
- steady flow in, 168, 173f
- stretch-sensitive, 163
- vascular wall remodeling in, 161
- IRF. *See* instrument response function
- isotropic cell spreading, 182
- karyopherins, 418
 - in nucleocytoplasmic transport, 422, 426
- katanin, 243
- key force-sensing/bearing proteins, structural
 - features of, 280t
- kinesin, 237
- kinetochores, 238
- K⁺ ion channels, 164
- KLF2. *See* Kruppel-like Factor-2
- Kramers reaction rate theory, 96
- Kruppel-like Factor-2 (KLF2), 48, 269
 - shear stress-induced changes in, 270f
- lamellar ruffling, 140
- lamellipodia, 37–38
 - actins and, 190
 - cell spreading in, 182
 - extension of, 190
 - fibronectin and, 189
 - microtubular mechanotransduction in, 239
 - periodic contractions in, 189–90
- laminin, 121
- lamins
 - in cell nuclei, 226
 - in NPCs, 432
 - in nucleocytoplasmic transport, 432
 - tensegrity in, 210
- large unilamellar vesicles (LUVs), 99
- lateral intercellular space (LIS), 342, 344, 346
 - ligand density and, 348–49, 352–54
- LDL. *See* low-density lipoprotein
- left descending anterior coronary artery (cLAD)
 - EC length in, 371f
 - SPA and, 370–71
- leucine-rich repeats (LRR), 308
- leukocytes, VCAM-1 proteins and, 307
- ligand(s), 214
- ligand binding
 - in disulfide bonds, 296–97
 - protein conformational change and, 273, 323
- ligand density
 - antibodies and, 135
 - autocrine signaling and, 344f, 346, 347–49
 - cell migration and, 135
 - cellular mechanotransduction regulation
 - by, 134–39
 - convection with, 356
 - diffusion and, 356
 - diffusion of, 351f
 - ECM and, 133–44
 - in EGF receptor, 353f
 - FE method for, 349
 - during haptotaxis, 134f
 - integrin binding to, 122, 136
 - kinetics of, 351f
 - LIS and, 347–49, 352–53
 - maximum rate of change for, 352f
 - motility control by, 135, 138
 - nonperturbing antibodies and, 137
 - regulation of, 137f
 - RGD peptides and, 122
 - three-dimensionality of ECM and, 148
- lipid bilayers, 91–101
 - caveolae in, 101
 - cholesterol in, 93
 - CMF in, 99–100
 - composition of, 97
 - diffusion rates for, 93
 - FCS for, 94, 95f, 96
 - FRAP and, 94, 96
 - free volume with, 97–98
 - GP in, 99
 - GUVs in, 97, 98f
 - HUVECs and, 94, 95f
 - hydrophilic headgroups in, 98
 - hydrophobic matching in, 92
 - Kramers reaction rate theory, 96
 - lateral fluidity of, 93–96
 - lateral stretching in, 92
 - LUVs in, 99
 - mechanical properties of, 91–93
 - membrane fluidity and, 97f, 281–82
 - membrane heterogeneity in, 100–1
 - membrane protein function in, 97

- lipid bilayers (*cont.*)
 - membrane tension between, 92–93, 99–100
 - molecular rotors in, 94
 - nonlamellar prone lipids in, 101
 - perturbation in, 93
 - polarity in, 98–99
 - raft domains in, 100
 - shear stress in, 92
 - structure of, 91–93
 - SUVs in, 98
 - thickness of, 92
 - transmembrane pressure profile in, 91, 91f
- lipid diffusion, within ECs, 74–75
- lipid domains, 68–69
 - BAECs in, 69, 70f
 - cholesterol in, 69
 - CT-B in, 69
 - membrane perturbation of, 71–72
 - membrane tension effects on, 74–75
 - rafts of, 68
 - shear stress in, 71f
 - wound closure and, 72
- lipid molecules, 65
 - fluidity of, 65, 67
 - G-proteins and, 67–68
 - hydrophilic portion of, 66
 - prestresses in, 207
- lipid perturbation, measurement tools for, 75–79
 - FCS, 75–76
 - FLIM, 79, 80f
 - fluorescence resonance energy transfer, 81
 - TCSPC, 75
- lipid rafts, 68
- LIS. *See* lateral intercellular space
- low-density lipoprotein (LDL), 308
- LRR. *See* leucine-rich repeats
- lungs
 - autocrine signaling in, 340f, 341
 - mechanical forces and, 287, 377
 - tensegrity in, 209
- LUVs. *See* large unilamellar vesicles
- magnesium, 126
- magnetic beads, tensegrity and, 204
- magnetic bead twisting cytometry, 32
- magnetic tweezers, 385–86
- magnetic twisting cytometry, 384–85
- malaria, 15
- manganese, 126, 127
- MAPK. *See* mitogen-activated protein kinase
- matrix metalloproteinases (MMPs), 150
- MD. *See* molecular dynamics
- mechanical forces, 286–89
 - with AFM, 380–82, 381f
 - blood flow and, 287
 - bone loading as, 287
 - on cells, 269–70, 407f
 - on ECM, 270, 377
 - examples of, in tissues, 404f
 - focal adhesion complexes and, 287, 288f
 - focal contracts and, 288
 - intracellular traction as, 288
 - lung motion as, 287, 377
 - with magnetic tweezers, 385–86
 - with magnetic twisting cytometry, 384–85
 - with microneedles, 379–80, 379f
 - with optical tweezers, 382–83
 - protein unfolding from, 289
 - traction as, 288
 - urine flow and, 287
- mechanobiology, 404–5
 - bone remodeling in, 404–5
 - definition of, 61
 - tissue remodeling in, 405–8
- mechanome, 15
- mechanosensation,
 - design criterion for, 12
 - in endothelium, 161
 - in G-protein mechanotransduction, 101–5
 - in vitro* tests of, 3–6, 4f
- mechanosensing, in cells, 181–91, 442
 - cell spreading in, 182
 - continuous protrusion in, 188–89
 - cytoskeletal organization in, 181–84
 - hierarchy of, 183
 - motility modules in, 181–82
 - motility phenotypes in, 181
 - nonlinearity in, 183
 - periodic lamellipodial contractions in, 189–90
 - properties of, 184–91
- mechanosensitive channels of large
 - conductance (MscL), 8, 14
 - as flow-sensitive, 171
- mechanosensors, 7
 - CSK, 90

Cambridge University Press

978-0-521-89523-1 - Cellular Mechanotransduction: Diverse Perspectives from Molecules to Tissues

Edited by Mohammad R. K. Mofrad and Roger D. Kamm

Index

[More information](#)

Index

457

- in cytoskeletal transduction, 10
- definition of, 61
- in endothelial mechanotransduction, 25
- membranes as, 61, 64–75
- mechanostat theory, 406
- mechanotransducers, 21
- mechanotransduction, cellular. *See also*
 - in vitro* tests, of mechanotransduction;
 - microtubules, cellular
 - mechanotransduction in
- advances in study of, 439–43
- through autocrine signaling in, 339–56
- breaking in, 234–44
- cell–cell junctional proteins in, 63
- cell force levels in, 12–15, 13t
- cell mechanosensing, 181–91
- computational tools for, 439–41
- cytoskeletal transduction in, 10
- definition of, 1
- design criterion for, 12
- in disease, 2–3
- disturbed flow in, 2
- ECM and, 120–51
- in endothelium, 20–52, 62
- external forces for, 386–87
- in focal adhesion complexes, 7f, 9–10, 247–61, 378
- force-bearing protein networks and, 287
- gene expression in, 10–11
- glyocalyx in, 10
- G-protein activation in, 89–109
- G-proteins in, 8–9, 33–34
- hearing and, 2
- hemodynamic shear stress and, 1
- historical development of, 1–2
- implications of, 211–13
- intracellular contraction in, 12
- ion channels in, 161–74
- ligand density regulation of, 134–39
- MD for, 439
- mechanisms of, 62–63
- mechanomes and, 15
- mechanosensors in, 7
- in membranes, 8–9
- membrane tensions during, 13
- microscale force techniques for, 377–96
- Monte Carlo methods for, 439
- multimodularity in, 286–328
- nanoscale force techniques for, 377–96
- NPC regulation of, 431–35
- nuclear mechanics and, 220–30
- in nuclear pore mechanics, 417–36
- nucleocytoplasmic transport regulation of, 417–36
- plasma membrane in, 61–81
- protein conformational change and, 269–82
- protein domain hinge motion and, 278
- protein structural basis for, 279–81
- protein unfolding in, 11
- proteoglycans in, 63
- reversible expansion in, 212
- at single molecule scale, 14
- soft tissue remodeling and, 1
- solvent treatment in, 440–41
- stress generation in, 2
- stretch-activated channels in, 7–8
- tensegrity in, 31–32, 196–214
- TFM in, 12
- tissue formation and, 213
- vascular physiology and, 62
- mechanotransmission, 23, 26–27
- melanoma cell adhesion molecules (Mel-CAM), 296
- melanoma cells, 127
- Mel-CAM. *See* melanoma cell adhesion molecules
- membrane heterogeneity, in lipid bilayers, 100–1
- phases of, 100
- membrane mechanotransduction, 8–9
 - G-proteins in, 8–9
 - in MAPK activation, 9
 - stress in, 9
- membrane perturbation, of lipid domains, 71–72
 - ERK and, 72
 - FRAP and, 71
- membrane proteins, 107
 - rhodopsin, 101, 107
 - transducin, 107
- mesenchymal stem cells (MSCs), 403
 - differentiation in, 413
 - tension strain on, 411, 413
- microbeads
 - fibronectin, 252
 - magnetic, tensegrity and, 204
 - in optical tweezers, 383

- microcantilevers, 392–95
 - Euler-Bernoulli beam theory and, 392
 - horizontal, 394
 - with micropost arrays, 393–94
- microfibrillar network, 130
- microfilament polymers, prestresses in, 210
- microneedles, 379–80, 379f
- micro-Newton forces, 387
- microscale force techniques, for cellular
 - mechanotransduction, 377–96
 - micro-Newton forces, 387
- microtubule networks, 27, 30
 - nuclear mechanics in, 228
 - tensegrity in, 207
- microtubules, cellular mechanotransduction
 - in, 234–44
 - actin filaments in, 241
 - APC and, 239
 - aPKC and, 239
 - bending of, 242–43
 - breaking of, 243–44
 - as cell transport, 237–38
 - collagen and, 234
 - deformation forces in, 240–44
 - depolymerization of, 243–44
 - direct mechanical stimulus in, 234
 - disruption of, 236
 - dynamic instability in, 238–40
 - in ECs, 234
 - in eukaryotic cells, 236
 - Euler Bucking model for, 237
 - externally applied force on, 241–42
 - GEF and, 244
 - katanin and, 243
 - kinesin in, 237
 - kinetochores in, 238
 - lamellipodium protrusion in, 239
 - molecular motors in, 241
 - myosin motors in, 241
 - nerve growth cone advance in, 238
 - PDGF and, 244
 - plus-end binding proteins in, 239
 - polarity, 237
 - polymerization forces in, 240, 242
 - roles of, 235–40
 - signaling cascades in, 239
 - signaling in, 238–40
 - stochastic switching in, 238
 - structure of, 235–37
 - thermal fluctuations in, 240
 - “whipped” structure in, 236
- mitogen-activated protein kinase (MAPK)
 - autocrine signaling through, 342
 - in integrin-mediated
 - mechanotransduction, 42
 - in ion channels, 162
 - in membrane mechanotransduction, 9
- mitosis
 - blebbing motility and, 187
 - kinetochores during, 238
 - nuclear mechanics and, 226–27
- MLC. *See* myosin light chain
- MLCK. *See* myosin light-chain kinase
- MMPs. *See* matrix metalloproteinases
- molecular dynamics (MD), 254
 - for autocrine signaling, 348
 - for cellular mechanotransduction, 439–40
 - for protein conformational change, 282
- SMD, 294
- molecular motors, 241
- molecular rotors, 94
- molecule force spectroscopy, 263
- monocytes, 2
- Monte Carlo methods, 439
- motility modules, 181–82
 - blebbing, 187–88
 - elements of, 190–91
 - filopodial, 186–87
 - global coordination, 183
 - hierarchy of, 183
 - myosin proteins and, 182
 - protein coding sequences in, 183
 - schematic for, 184f
 - types of, 184–85, 185f
- motor proteins, 121
 - myosin superfamily in, 130
- MRLC. *See* myosin regulatory light-chains
- MscL. *See* mechanosensitive channels of
 - large conductance
- MSCs. *See* mesenchymal stem cells
- multimodularity, in cellular
 - mechanotransduction, 286–328
 - in eukaryotic cells, 289
 - module stability and, 298
 - protein features as result of, 289–94
- multimodular proteins, 38, 289–94
 - α -actinin, 121, 310, 311f, 312–14, 315
 - ankyrin, 315–16

- ankyrin repeats in, 291–92
- calmodulin, 294–95
- common structural modules in, 293t
- cytoplasmic domain in, 318
- FERM domains in, 318
- fibronectins in, 291f, 308, 309f, 310
- filamin, 316
- force-sensitive signals in, 321
- FRET for, 291f, 326, 328
- GFP, 38, 294
- Ig-like domains in, 291
- integrin-mediated cell adhesions and, 318
- “low sequence identities” in, 299
- mechanical stability of, 298–99, 317, 327f
- modular structure/binding sites of, 307f
- PC1, 308, 309f, 310
- p130Cas, 290f, 303–4
- PTB domains in, 318
- response to force, 294–95
- shearing of, 295
- SMD for, 294, 325
- β -strands, 290–91, 312
- thermodynamic stability of, 294
- titin, 280, 304, 307
- unfolding of, 325f
- unzipping of, 294–95
- VCAM-1, 293, 307–8
- WLCs and, 315
- Murray’s Law, 1, 20
- Murzin, Alexey, G., 279
- muscle cells, 269
 - SMCs, ECs and, 174
 - tensegrity in, 209
 - titin proteins in, 280
- musculoskeletal system, impulsive forces on, 377
- myosin light chain (MLC), 42
 - MRLC, 187
- myosin light-chain kinase (MLCK), 130
- myosin motors, in microtubular
 - mechanotransduction, 241
- myosin proteins, 130
 - actins and, 190
 - blebbing motility and, 187
 - blebbistatin for, 139, 144
 - contractions for, 143
 - in ECM, 251
 - ELCs, 130
 - filopodial motility and, 186
 - MLCK, 130
 - motility modules and, 182
 - protein domain hinge motion and, 277
 - regulation of, 130
 - myosin regulatory light-chains (MRLC), 187
- nanoscale force techniques, for cellular
 - mechanotransduction, 377–96
- nerve growth cone advance, 238
- neutrophils, shear stress and, 105
- nitric oxide (NO), 35
 - in endothelium, 90
 - in G-protein mechanotransduction, 107–8
 - with SPA, 367
- NO. *See* nitric oxide
- nonlamellar prone lipids, 101
- NPCs. *See* nuclear pore complexes in
- nuclear envelope, 223f
 - deformability of, 224f
 - lamina in, 226
- nuclear lamins, 210
- nuclear mechanics, 220–30
 - actin filaments and, 228
 - adhering cells in, 225, 228
 - in biochemistry, 220
 - cell measurements in, 222
 - chromatins in, 225
 - at chromosome level, 227
 - in cytoplasmic cell region, 223–24, 230
 - deformations in, 226
 - disease and, 227–28
 - double-membrane envelope in, 223
 - ECs and, 220
 - force–deformation relationship in, 221
 - future directions for, 228, 230
 - GFP-LamA in, 224f
 - intracellular loading in, 230
 - intrinsic strain in, 225
 - lamina in, 226
 - macroscopic properties in, 222–24
 - in microtubules, 228
 - mitosis and, 226–27
 - morphological change in, 225
 - nuclear envelope in, 223f
 - organelles in, 230
 - properties in, 221
 - signaling pathways in, 220
 - strain state in, 225
 - subnuclear components in, 225–27

- nuclear mechanics (*cont.*)
 - tensegrity model in, 225
 - viral infections and, 226
- nuclear pore complexes (NPCs), 417–20, 422
 - anatomy of, 419f
 - cellular mechanotransduction regulation
 - by, 431–35
 - as control feedback system, 425f, 434
 - FG repeats in, 417–18
 - importins in, 418
 - karyopherins in, 418
 - lamins and, 432
 - mode shapes for, 424f
 - nucleocytoplasmic transport and, 418, 427–31
 - plane deforming in, 421f
 - stress generation within, 421f
 - tensegrity in, 210
 - in yeast/vertebrates, 420f
- nuclear pore mechanics, 417–36
- nucleated cells, 203f
- nucleocytoplasmic transport, 417–36
 - cellular mechanotransduction regulation
 - by, 417–36
 - control feedback system for, 425f
 - FG repeats in, 425–26, 430–31
 - importins in, 423, 425–26
 - karyopherins in, 422, 426
 - modes of, 429f
 - molecular biology of, 422–23, 425–27
 - NPCs and, 418, 427–31
 - simulation of, 427f
 - stages of, 426–27
 - structure of, 423f
- nucleus, in cells,
 - adhering cells in, 225
 - intrinsic strain in, 225
 - isolation of, 222–23
 - lamina in, 226
 - measurements for, 222
 - morphological change in, 225
 - strain state of, 225
- optical tweezers, 286, 382–83
 - microbeads in, 383
- organelles, 230
- oscillatory flow
 - in ion channels, 168, 172–74
 - in WSS, 366
- osteoblasts, 405
- osteoclasts, 405
- “outside-in signaling,” 127–29, 139
 - tyrosine phosphorylation and, 127
- PAK. *See* p-21 activated kinase
- paxillin molecules, 128
 - filopodial motility and, 186
 - three-dimensionality of ECM and, 146–47
- PC1 protein. *See* polycystin-1 protein
- PDGF. *See* platelet-derived growth factor
- PDMS. *See* pre-stretched
 - polydimethylsiloxane
- PECAM-1. *See* platelet-endothelial cell
 - adhesion molecule-1
- periodic contractions, in lamellipodia, 189–90
 - collapsing, 189
 - leading edge extension during, 189
 - transient extraction during, 189
- permeabilized cells, 204
- phenotypes, in endothelium
 - mechanotransduction, 45–47
 - atherogenic, 62
 - atheroprotective, 47
- phenylalanine-glycine (FG) repeats, 417–18
 - chains for, 428f
 - in nucleocytoplasmic transport, 425–26, 430–31
- phospholipase C (PLC), 188
- phospholipids, in cell membranes, 65
- phosphotyrosine binding (PTB) domains, 126
 - FERM domains and, 126
 - in multimodular proteins, 318
- PHSRN peptides. *See* pro-his-ser-arg-asn
 - peptides
- PKC. *See* protein kinase C
- PKD. *See* polycystic kidney disease
- plasma membrane, in cellular
 - mechanotransduction, 61–81
 - ECs in, 61
 - homeostasis in, 61
 - mechanosensors in, 61
- platelet-derived growth factor (PDGF), 244
- platelet-endothelial cell adhesion molecule-1 (PECAM-1), 24, 44
 - ion channels and, 161
- PLC. *See* phospholipase C
- Plexiglas, 236
- plus-end binding proteins, 239

- Poisson's ratio, 140
- polarity, in lipid bilayers, 98–99
- polycystic kidney disease (PKD), 2
 - modules for, 299
 - PC1 and, 308, 310
- polycystin-1 (PC1) protein, 308, 310
 - LDL and, 308
 - LRR and, 308
 - modular structure/binding sites for, 309f
 - PKD and, 308, 310
 - TRP channels, 308
 - WSC and, 308
- polycystins, 213
 - PC1, 308, 309f, 310
- p130Cas proteins, 290f, 303–4
 - scaffolding molecules in, 303
 - structure/binding sites of, 305f
 - Triton X and, 303
- prestresses, tensegrity and, 197, 199, 205f, 206, 210, 213
 - computer models for, 201f
 - in cytoskeletal proteins, 205f, 206
 - in lipids, 210
 - in microfilament polymers, 210
 - in viruses, 210
- pre-stretched polydimethylsiloxane (PDMS), 302
- primary cilium, 22, 26, 36
 - TRP channels in, 36
- pro-his-ser-arg-asn (PHSRN) peptides, 124
- protein(s). *See also* G-proteins, in cellular mechanotransduction; membrane proteins; motor proteins; multimodular proteins; myosin proteins; unfolding, of proteins
 - adhesion-complex, 279–80
 - amino acids, 274
 - ankyrin, 316–17
 - biomolecule transport in, 270
 - catalytic functions of, 270
 - cell-cell junctional, 63
 - “clamped” regions in, 295
 - coat, 42
 - conformational change of, 269–82
 - constitutive models of, 276–77
 - cytoskeletal, ECM v., 120–21
 - deformation modes in, 271–72, 272f
 - disulfide bonds and, 295–97
 - domains, 271–72
 - features of, from cellular mechanotransduction, 289–94
 - fibronectin, 280, 299–300, 302–3
 - filamin, 316
 - filopodial motility and, 186
 - force-bearing networks of, 287
 - force sensing, 254–59, 261
 - genetic information transmission in, 270
 - GPI-anchored, 34
 - integrins, 280
 - interactions with other proteins, 275
 - key force-sensing/bearing, structural features of, 280t
 - lipid fluidity in, 67
 - mechanical stability of, 294
 - mechanics of, 275–81
 - metabolic functions of, 270
 - in motility modules, coding sequences for, 183
 - multimodular, 289–94
 - PC1, 308, 309f, 310
 - plus-end binding, 239
 - p130Cas, 290f, 303–4
 - Rho, 251–52
 - SCOP for, 279
 - signal transduction in, 270
 - single molecule mechanoresponse techniques for, 323–24
 - structural features of, 271f, 292f
 - structural support within, 270
 - titin, 280, 304, 307
 - unfolding, 289
 - VCAM-1, 293, 307–8
- protein conformational change, 269–82
 - with AFM, 303–24
 - amino acids in, 274
 - biological consequences of, 270–75
 - domain deformation as, 271–72, 272f
 - domain motion as, 271
 - domain unfolding as, 271
 - ECM and, 269
 - ECs and, 269
 - experimental approaches to, 320–26, 328
 - fluorescence approaches to, 325–26, 328
 - force-induced, 275
 - FRET for, 282, 323
 - GFP and, 326–27, 328
 - ligand binding and, 273, 323
 - MD simulations for, 282

- protein conformational change (*cont.*)
 mechanical forces responses by, 269–70
 modeling for, 281–82
 population stretching tools for, 321–22
 single molecule biomechanics studies for, 281–82
 SMD and, 324–25
 spatial/temporal regulation in, 275
 vWF as, 273, 280
- protein domain elongation, 272
- protein domain hinge motion, 271–72, 277–78
 mechanochemical coupling and, 278
 mechanotransduction and, 278
 myosin proteins and, 277
 receptor–ligand binding and, 278–79
- protein domain slide motion, 272
- protein inclusions, membrane tension effects on, 74–75
- protein kinase C (PKC), 47–48
 atypical, 239
- protein unfolding, 11
 computational methods for, 11
- proteoglycans, in cellular
 mechanotransduction, 63
- protrusive forces, in ECM, 129
- PTB domains. *See* phosphotyrosine binding domains
- p-21 activated kinase (PAK), 44–45
- pulmonary disease, 2
- qTIRFM. *See* quantitative total Internet reflection fluorescence microscopy
- quantitative total Internet reflection fluorescence microscopy (qTIRFM), 73
- raft domains, 100–1
- receptor–ligand binding, 278–79
- red blood cells, CMF in, 100
- reversible expansion, in
 mechanotransduction, 212
- RGD peptides,
 β -actinin and, 122
 in ECM, 438
 integrin binding and, 122
 PHSRN, 124
- rhodopsin, 101
- Rho proteins, 251–52
- Saffman hydrodynamic theory, 100
- SA ion channels. *See* stress-activated ion channels
- SCOP. *See* Structural Classification of Proteins
- SED. *See* strain energy density
- shear modulus, 140
- shear stress
 BAECs and, 89
 EC wound closure and, 72
 on endothelial mechanotransduction, 21f, 33–36, 44–45
 on endothelium, 89, 105
 finite element analysis for, 73–74
 focal adhesion and, 74f
 glycocalyx in, 5
 in GPCR, 102
 in lipid bilayers, 92
 in lipid domains, 71f
 on membranes, 73–74
 neutrophils and, 105
 quantification of, in membranes, 73–74
 in vitro tests with, 3–5
 VRAC and, 33
- signal amplification cascades, 102
- signaling pathways
 dynamic instability and, 238–40
 in microtubular mechanotransduction, 238–40
 in nuclear mechanics, 220
- sinusoidal input functions, 29
- small unilamellar vesicles (SUVs), 98
- SMCs. *See* smooth muscle cells
- SMD. *See* steered molecular dynamics
- smoking, 89
- smooth muscle cells (SMCs), 174
 phenotype of, 405
 tension strain on, 410
- soft glassy material models, 32
- soft tissue remodeling, 1
- solvents, 440–41
- SPA. *See* stress phase angle
- spatiotemporal displacement patterns, 40
- spectrin repeats, 310, 315
- sphingolipids, 101
- steady flow, in ion channels, 168, 173f
- steered molecular dynamics (SMD), 294
 for α -actinin, 313, 315f
 for multimodular proteins, 294, 324

- protein conformational change and, 324–25
- unfolding proteins and, 326f
- stem cells, 269
 - compression effects on, 408–10, 411f, 412–13
 - compression strain devices for, 409f
 - in ECM, 143
 - EPCs, 403
 - HSCs, 403
 - mechanical regulation of, 403–14
 - MSCs, 403
 - tensile strain devices for, 409f
 - tension effects on, 408–10, 411f, 412–13
- stereocilia of hair cells, in stretch-activated channels, 8
- “stick and string” tensegrity model, 208
- stochastic switching, 238
- strain energy density (SED), 373
- β -strands, 290–91, 312
- stress-activated (SA) ion channels, 198
 - mechanical properties of, 211
- stresses
 - in membrane mechanotransduction, 9
 - within NPCs, 421f
- “stress fibers”, 206
- stress phase angle (SPA)
 - cLAD and, 370–71
 - CS/WSS and, 361–74
 - EECP and, 372
 - eNOS with, 369
 - influence factors for, 362–63, 365
 - NO release with, 367
 - studies with, 366–67
 - variable, 367–72
- stretch-activated channels, 7–8
 - conductance changes in, 8
 - MscL, 8, 14
 - in stereocilia of hair cells, 8
- stretch-sensitive ion channels, 163
- Structural Classification of Proteins (SCOP), 279
- struts, compression, 207
- substrate stretch tests, 5–6
 - biaxial, 5
 - uniaxial, 5
- SUVs. *See* small unilamellar vesicles
- talin
 - activation of, 262
 - binding mechanism for, 257, 259, 261, 264f, 320
 - in focal adhesion complexes, 254–56, 255f
 - force-induced activation of, 256–59
 - hydrophobic residues in, 261
 - under molecule force spectroscopy, 263
 - solvent effects for, 258–59
 - structure of, 256, 257f, 259, 260f
 - VBS in, 256–59, 261, 262f
 - wild-type, 263
- TCSPC microscopy. *See* time-correlated single photon counting microscopy
- tensegrity, in cellular mechanotransduction, 31–32, 196–214
 - architecture of, 199–202
 - artistic representations of, 200f
 - in blood cells, 209
 - in cartilage, 209
 - cell metabolism and, 197
 - cells and, 202–6
 - cell stiffness and, 204
 - cytoskeletal proteins and, 197, 209–10
 - definition of, 199
 - in ECM, 197, 203, 208–9
 - in epithelial tissues, 209
 - exogenous mechanical loads and, 196
 - focal adhesion complexes and, 203
 - FRAP and, 206
 - in GFP, 207
 - hierarchy in, 201f, 208–11
 - integrins and, 203
 - ligands and, 204
 - in lungs, 209
 - magnetic beads and, 204
 - in microtubules, 207
 - at molecular level, 206–8
 - in musculoskeletal system, 209
 - in nuclear lamins, 210
 - in nuclear mechanics, 225
 - in nuclear pore complexes, 210
 - in nucleated cells, 203f
 - permeabilized cells and, 204
 - prestresses and, 197, 199, 205f, 206, 210, 213
 - rheological measurements and, 205
 - SA ion channels and, 198

- tensegrity, in cellular mechanotransduction
(*cont.*)
at single cell level, 201, 203
spherical, 202f
“stick and string” model for, 208
“stress fibers” and, 206
structural rigidity and, 200
in subcellular structures, 210
three-dimensional mapping technique for, 204
transduction molecules and, 198
- tension field theory, 33
- tension strain, on stem cells, 408–10, 412–13
devices for, 409f
for ESCs, 410
MSCs, 410, 413
SMCs, 410
- TFM. *See* traction force microscopy
- thin film buckling, 388
- three-dimensionality of ECM, 144–50
cell migration and, 146, 149f
cell shape and, 144–46
cellular mechanosensing and, 150
computational models of, 148–49
FAK and, 146–48
fibers in, 148
fibroblasts and, 147
ligand density and, 148
matrix density and, 150
mechanical tension in, 148
paxillin molecules and, 146–48
- three-dimensional adhesions, 129
- thrombosis, 269
- time-correlated single photon counting (TCSPC) microscopy, 75
optical set-up for, 77f
- tissue remodeling, 405–8
- titin proteins, 280, 304, 307
modular structure/binding sites of, 306f
- towed growth, in cells, 234
- traction force microscopy (TFM), 12, 389f
for elastic substrata, 389
- traction forces
BDM and, 133
cell production of, 131, 132f
in cytoskeleton, 129–31
EC generation of, 133
in ECM, 129–33, 139
elasticity and, 133
elastic substrata in, 389–92
FAK and, 392
GFP for, 391
intracellular, 288
localized, 132
measurement of, 387
as mechanical force, 288
with microcantilevers, 392–95
microdot arrays for, 391f
pinching force, 131
TFM, 12, 389f
thin film buckling and, 388
wrinkling silicone membranes and, 387–89
- transducin, 107
- transduction molecules, 198
- transient receptor potential (TRP) channels, 36
in flow-sensitive ion channels, 163
HAECs in, 163
PC1 proteins and, 308
- Triton, X, 9
p130Cas protein and, 303
- TRP channels. *See* transient receptor potential channels
- tumor cells, migration of, 187
- tweezers. *See* magnetic tweezers; optical tweezers
- two-photon microscopy, 343f, 354
- 2,3-butanedione monoxime (BDM), 252, 253
- tyrosine phosphorylation, 127
- unfolding, of proteins, 289
ciliary vibrations and, 289
cysteines and, 289
in eukaryotic cells, 289
in fibronectin, 300, 302
mechanical stability in, 296
in multimodular proteins, 325f
peak-forces on, 296f
SMD and, 326f
- unilamellar vesicles, FCS for, 76–78
- vascular cell adhesion molecule-1 (VCAM-1)
proteins, 293, 307–8
disulfide bonds and, 295, 297f
ICAM-1, 307
leukocytes and, 307
modular structure/binding sites of, 307

- vascular physiology
 - cellular mechanotransduction and, 62
 - glycocalyx in, 69–70
 - membranes in, as mechanosensors, 64–75
 - tensegrity in, 209
- vasoactive peptides, 104
- VBS. *See* vinculin binding sites
- VCAM-1. *See* vascular cell adhesion molecule-1 proteins
- vinculin
 - activation of, 258f, 259, 262
 - binding mechanism of, 259, 261, 264f
 - in focal adhesion complexes, 254–55
 - hydrophobic residues in, 261
 - under molecule force spectroscopy, 263
 - structure of, 259, 263
 - VBS and, 256–59
- vinculin binding sites (VBS), 256–59, 261
 - activation of, 258f, 259
 - binding simulation of, 263
- viral infections, 226
- viruses, prestresses in, 210
- viscoelastic models, 30, 31t, 32
- viscous modulus, 30
- vitronectin, 134
- volume-regulated anion current (VRAC), 33
 - in Cl⁻ ion channels, 166
- von Willebrand Factor (vWF), 273, 280
- VRAC. *See* volume-regulated anion current
- vWF. *See* von Willebrand Factor
- wall integrity and stress component (WSC), 308
- wall shear stress (WSS), 360–74
 - carotid bifurcation model for, 364f
 - in ECs, 361f, 365–72
 - influencing factors for, 362–63, 365
 - intercellular junctions and, 373
 - oscillatory flow in, 366
 - physiological background of, 360–65
 - SED and, 373
 - simultaneous stretch/shear methods in, 365–66
 - SPA and, 361–74
 - stretch/shear mechanism for, 372–73
 - tension in, 373
- WAVE1, 189
- wild-type talin, 263
- WLCs. *See* worm-like chains
- Wolff's Law, 1, 406
- worm-like chains (WLCs), 315
- wound healing
 - ECM and, 134
 - lipid fluidity and, 72
- wrinkling silicone membranes, 387–89
- WSC. *See* wall integrity and stress component
- WSS. *See* wall shear stress
- Zamir's Law, 20